Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality. Treatment can be challenging due to medication-associated toxicities. Marib...

Full description

Saved in:
Bibliographic Details
Main Authors: Lauren Ogawa, Chelsea Morinishi, Ashrit Multani, Pryce Gaynor, Omer E. Beaird, Christine Pham, Joanna M. Schaenman
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Viruses
Subjects:
CMV
resistance
maribavir
foscarnet
immunocompromised
Online Access:https://www.mdpi.com/1999-4915/16/12/1889
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4915/16/12/1889

Similar Items